Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Bristo-Myers Shares Rise on Drug Trial Results in Bloomberg, By Drew Armstrong Oct 28, 2013

Excerpt:
"Bristol-Myers Squibb Co. (BMY) rose to its highest closing price since 2001 after releasing trial results that showed its experimental drugs for lung cancer and rheumatoid arthritis helped patients.

Bristol-Myers rose 6.7 percent to $52.02 at 4 p.m. New York time, the highest closing value since December 2001 and the biggest one-day gain since March 2009. The New York-based company released data over the weekend that showed its top pipeline project, an immune-system based cancer treatment, extended the lives of lung cancer patients. The company’s experimental rheumatoid arthritis treatment was found to be about as effective as a current standard treatment sold by AbbVie Inc. (ABBV), a study found.

In a trial of 418 rheumatoid arthritis patients, 78 percent of those who took Bristol-Myers’s clazakizumab with methotrexate reduced their symptoms by at least 20 percent, the company said. That was twice the rate of patients who took only methotrexate, a generic treatment for the disease. Of patients taking methotrexate and Humira, AbbVie’s injectable drug that sold $9.27 billion last year, 76 percent had symptoms fall by at least 20 percent.

“It’s encouraging, especially since they had a comparator arm there with Humira plus methotrexate,” said Grant Louie, a rheumatologist and professor of medicine at Johns Hopkins University School of Medicine. “It does appear to be comparable.”

Article at:
http://www.bloomberg.com/news/2013-10-28/bristo-myers-shares-rise-on-drug-trial-results.html